Imperial College London
Alternate

Walter Distaso

Business School

Professor of Financial Econometrics
 
 
 
//

Contact

 

+44 (0)20 7594 3293w.distaso Website

 
 
//

Location

 

3.0253 Prince's GateSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Izzi-Engbeaya:2021:10.1136/bmjdrc-2020-001858,
author = {Izzi-Engbeaya, C and Distaso, W and Amin, A and Kenkre, J and Abdel-Malek, M and Hope, D and Oliver, N and Misra, S and Tan, T and Hill, N and Salem, V},
doi = {10.1136/bmjdrc-2020-001858},
journal = {BMJ Open Diabetes Research and Care},
pages = {1--10},
title = {Adverse outcomes in COVID-19 and diabetes – a retrospective cohort study from three London Teaching hospitals},
url = {http://dx.doi.org/10.1136/bmjdrc-2020-001858},
volume = {9},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Patients with diabetes mellitus admitted to hospital with COVID-19 have poorer outcomes. However, the drivers for this are not fully elucidated.  We performed detailed characterisation of COVID-19 patients to determine clinical and biochemical factors that may be the drivers of poorer outcomes. RESEARCH   DESIGN   AND   METHODS:   Retrospective   cohort   study   of   889 consecutive inpatients diagnosed with COVID-19 between 9th March 2020 and 22nd April  2020  in  a  large  London  NHS  Trust.  Unbiased multivariate logistic  regression analysis  was  performed  to  determine  variables  that were independently  and significantly associated with increased risk of death and/or ICU admission within 30 days of COVID-19 diagnosis. RESULTS: 62% of patients in our cohort were of non-White ethnic backgrounds and the diabetes prevalence was 38%.  323 (36%) patients met the primary outcome of death/admission  to  the  intensive  care  unit  (ICU)  within  30  days  of  COVID-19 diagnosis.    Male  gender,  lower  platelet  count,  advancing  age  and  higher  Clinical Frailty Scale (CFS) score (but not diabetes) independently predicted poor outcomes on multivariate analysis.  Antiplatelet medication was associated with a lower risk of death/ICU admission. Factors that were significantly and independently associated with  poorer  outcomes  in  patients  with  diabetes  were  co-existing  ischaemic  heart disease, increasing age and lower platelet count. CONCLUSIONS: In this large study of a diverse patient population, comorbidity (i.e. diabetes with ischaemic heart disease; increasing CFS score in older patients) were major determinants of poor outcomes with COVID-19. Antiplatelet medication should be evaluated in randomised clinical trials amongst high-risk patient groups.
AU  - Izzi-Engbeaya,C
AU  - Distaso,W
AU  - Amin,A
AU  - Kenkre,J
AU  - Abdel-Malek,M
AU  - Hope,D
AU  - Oliver,N
AU  - Misra,S
AU  - Tan,T
AU  - Hill,N
AU  - Salem,V
DO  - 10.1136/bmjdrc-2020-001858
EP  - 10
PY  - 2021///
SN  - 2052-4897
SP  - 1
TI  - Adverse outcomes in COVID-19 and diabetes – a retrospective cohort study from three London Teaching hospitals
T2  - BMJ Open Diabetes Research and Care
UR  - http://dx.doi.org/10.1136/bmjdrc-2020-001858
UR  - https://drc.bmj.com/content/9/1/e001858
UR  - http://hdl.handle.net/10044/1/84807
VL  - 9
ER  -
Download